Oncology Reviews最新文献_第5页

Changing Colorectal Cancer Trends in Asians: Epidemiology and Risk Factors. 亚洲人结直肠癌趋势的变化:流行病学和危险因素。

IF 3.6

Oncology Reviews Pub Date : 2023-01-01 DOI: 10.3389/or.2023.10576

Carissa Ikka Pardamean, Digdo Sudigyo, Arif Budiarto, Bharuno Mahesworo, Alam Ahmad Hidayat, James W Baurley, Bens Pardamean

引用次数: 1

Challenges and Opportunities Associated With Drug Delivery for the Treatment of Solid Tumors. 实体肿瘤治疗药物传递的挑战与机遇。

IF 3.6

Oncology Reviews Pub Date : 2023-01-01 DOI: 10.3389/or.2023.10577

Teona Paresishvili, Zurab Kakabadze

{"title":"Challenges and Opportunities Associated With Drug Delivery for the Treatment of Solid Tumors.","authors":"Teona Paresishvili, Zurab Kakabadze","doi":"10.3389/or.2023.10577","DOIUrl":"https://doi.org/10.3389/or.2023.10577","url":null,"abstract":"In this review, we discuss the effectiveness of drug delivery system based on metal nanoparticles, and also, describe the problems associated with their delivery to tumor cells. Throughout recent years, more reports have appeared in the literature that demonstrate promising results for the treatment of various types of cancer using metal-based nanoparticles. Due to their unique physical and chemical properties, metal nanoparticles are effectively being used for the delivery of drug to the tumor cells, for cancer diagnosis and treatment. They can also be synthesized allowing the control of size and shape. However, the effectiveness of the metal nanoparticles for cancer treatment largely depends on their stability, biocompatibility, and ability to selectively affect tumor cells after their systemic or local administration. Another major problem associated with metal nanoparticles is their ability to overcome tumor tissue barriers such as atypical blood vessel structure, dense and rigid extracellular matrix, and high pressure of tumor interstitial fluid. The review also describes the design of tumor drug delivery systems that are based on metal nanoparticles. The mechanism of action of metal nanoparticles on cancer cells is also discussed. Considering the therapeutic safety and toxicity of metal nanoparticles, the prospects for their use for future clinical applications are being currently reviewed.","PeriodicalId":19487,"journal":{"name":"Oncology Reviews","volume":"17 ","pages":"10577"},"PeriodicalIF":3.6,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10497757/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10321420","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Deciphering Driver of Nasopharyngeal Cancer Development. 破译鼻咽癌发展的驱动因素

IF 3.1

Oncology Reviews Pub Date : 2022-10-11 eCollection Date: 2022-01-01 DOI: 10.3389/or.2022.10654

Handoko, Melva Louisa, Tiara Bunga Mayang Permata, Soehartati A Gondhowiardjo

引用次数: 0

Molecular drivers of oral cavity squamous cell carcinoma in non-smoking and non-drinking patients: what do we know so far? 不吸烟和不饮酒患者口腔鳞状细胞癌的分子驱动因素：我们目前了解多少？

IF 3.1

Oncology Reviews Pub Date : 2022-02-22 DOI: 10.4081/oncol.2022.549

Sophia Uddin, Alka Singh, Vasudha Mishra, Nishant Agrawal, Zhen Gooi, Evgeny Izumchenko

引用次数: 0

Glucose transporters as markers of diagnosis and prognosis in cancer diseases 葡萄糖转运蛋白在肿瘤疾病诊断和预后中的作用

IF 3.6

Oncology Reviews Pub Date : 2022-02-22 DOI: 10.4081/oncol.2022.561

L. Szablewski

引用次数: 12

A Review of Studies on the Seasonal Variation of Indoor Radon-222 Concentration. 室内氡-222浓度的季节变化研究综述。

IF 3.6

Oncology Reviews Pub Date : 2022-01-01 DOI: 10.3389/or.2022.10570

Guadie Degu Belete, Aragaw Msganaw Shiferaw

{"title":"A Review of Studies on the Seasonal Variation of Indoor Radon-222 Concentration.","authors":"Guadie Degu Belete, Aragaw Msganaw Shiferaw","doi":"10.3389/or.2022.10570","DOIUrl":"https://doi.org/10.3389/or.2022.10570","url":null,"abstract":"Due to their electrostatic nature, radon decay products can attach to solid particles and aerosols in the air. Inhalation and ingestion are therefore the two main routes through which people are exposed to radon and its decay products. During the inhalation of these radioactive aerosols, deposition takes place in different regions of the human respiratory tract. The deposited aerosols carrying radon and its progeny undergo a continuous radioactive transformation and expose the lung to ionizing alpha radiation, which can destroy the sensitive cells in the lung, causing a mutation that turns cancerous. Radon which is a colorless, odorless, and tasteless radioactive noble gas is a major health concern and is the second leading cause of lung cancer. To address this, an indoor radon survey was conducted in many countries internationally, with results showing that indoor radon concentration has a seasonal variation. This is due to the fluctuation of environmental parameters and the geological nature of buildings. Its concentration was found to be maximum in the cool (winter) season and a minimum concentration was recorded in the warm (summer) season of the year.","PeriodicalId":19487,"journal":{"name":"Oncology Reviews","volume":"16 ","pages":"10570"},"PeriodicalIF":3.6,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9756844/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10749218","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 3

The effect of imatinib and nilotinib on blood calcium and blood potassium levels in chronic myeloid leukemia patients: a literature review. 伊马替尼和尼洛替尼对慢性髓系白血病患者血钙、血钾水平的影响:文献综述。

IF 3.6

Oncology Reviews Pub Date : 2021-11-26 eCollection Date: 2021-09-21 DOI: 10.4081/oncol.2021.547

Muhammad Darwin Prenggono, Alfi Yasmina, Misna Ariyah, Tenri Ashari Wanahari, Nuvita Hasrianti

{"title":"The effect of imatinib and nilotinib on blood calcium and blood potassium levels in chronic myeloid leukemia patients: a literature review.","authors":"Muhammad Darwin Prenggono, Alfi Yasmina, Misna Ariyah, Tenri Ashari Wanahari, Nuvita Hasrianti","doi":"10.4081/oncol.2021.547","DOIUrl":"https://doi.org/10.4081/oncol.2021.547","url":null,"abstract":"Imatinib and nilotinib are first-line treatments for chronic myeloid leukemia (CML) patients, which act specifically against target cells. However, these drugs may cause side effects, such as electrolyte disturbances. This literature review aimed to provide a comparison of the effects of imatinib and nilotinib on blood potassium and calcium levels. It also summarized their hypothetical mechanism. A comprehensive electronic search of the different databases was conducted using 'chronic myeloid leukemia', 'tyrosine kinase inhibitors', 'imatinib', 'nilotinib', 'potassium', 'calcium', 'electrolytes' as keywords. This review used PubMed- MEDLINE, Cochrane Library, and Google Scholar as the source databases. Sixteen articles published from 2006 to 2020 were reviewed. Changes in blood potassium levels range from increased to decreased levels, while changes in blood calcium levels range from the lower normal values to below normal values (hypocalcemia). Tyrosine kinase inhibitors (TKIs), including imatinib and nilotinib, have a non-specific target, namely plateletderived growth factor receptor (PDGFR), which indirectly affects blood potassium and calcium levels in CML patients. The clinical manifestations of these changes vary from being visible only in laboratory tests to displaying a variety of clinical signs and symptoms.","PeriodicalId":19487,"journal":{"name":"Oncology Reviews","volume":"15 2","pages":"547"},"PeriodicalIF":3.6,"publicationDate":"2021-11-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/c6/a0/onco-15-2-547.PMC8649642.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39892116","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 2

Donafenib in Chinese patients with advanced hepatocellular carcinoma (HCC): Really a new standard of care, or should we change paradigm for drug development in HCC? 多纳非尼在中国晚期肝细胞癌(HCC)患者中的应用:真的是一个新的治疗标准，还是我们应该改变HCC药物开发的模式?

IF 3.6

Oncology Reviews Pub Date : 2021-09-22 eCollection Date: 2021-09-21 DOI: 10.4081/oncol.2021.564

Francesca Negri, Camillo Porta

引用次数: 4

Molecular insights and clinical impacts of extracellular vesicles in cancer. 细胞外囊泡在癌症中的分子见解和临床影响。

IF 3.6

Oncology Reviews Pub Date : 2021-09-21 DOI: 10.4081/oncol.2021.542

Kittinun Leetanaporn, Jitti Hanprasertpong, Raphatphorn Navakanitworakul

引用次数: 1

The repair gene BACH1 - a potential oncogene. 修复基因BACH1 -一个潜在的致癌基因。

IF 3.6

Oncology Reviews Pub Date : 2021-07-02 eCollection Date: 2021-02-26 DOI: 10.4081/oncol.2021.519

Katheeja Muhseena N, Sooraj Mathukkada, Shankar Prasad Das, Suparna Laha

{"title":"The repair gene BACH1 - a potential oncogene.","authors":"Katheeja Muhseena N, Sooraj Mathukkada, Shankar Prasad Das, Suparna Laha","doi":"10.4081/oncol.2021.519","DOIUrl":"https://doi.org/10.4081/oncol.2021.519","url":null,"abstract":"BACH1 encodes for a protein that belongs to RecQ DEAH helicase family and interacts with the BRCT repeats of BRCA1. The N-terminus of BACH1 functions in DNA metabolism as DNA-dependent ATPase and helicase. The C-terminus consists of BRCT domain, which interacts with BRCA1 and this interaction is one of the major regulator of BACH1 function. BACH1 plays important roles both in phosphorylated as well as dephosphorylated state and functions in coordination with multiple signaling molecules. The active helicase property of BACH1 is maintained by its dephosphorylated state. Imbalance between these two states enhances the development and progression of the diseased condition. Currently BACH1 is known as a tumor suppressor gene based on the presence of its clinically relevant mutations in different cancers. Through this review we have justified it to be named as an oncogene. In this review, we have explained the mechanism of how BACH1 in collaboration with BRCA1 or independently regulates various pathways like cell cycle progression, DNA replication during both normal and stressed situation, recombination and repair of damaged DNA, chromatin remodeling and epigenetic modifications. Mutation and overexpression of BACH1 are significantly found in different cancer types. This review enlists the molecular players which interact with BACH1 to regulate DNA metabolic functions, thereby revealing its potential for cancer therapeutics. We have identified the most mutated functional domain of BACH1, the hot spot for tumorigenesis, justifying it as a target molecule in different cancer types for therapeutics. BACH1 has high potentials of transforming a normal cell into a tumor cell if compromised under certain circumstances. Thus, through this review, we justify BACH1 as an oncogene along with the existing role of being a tumor suppressant.","PeriodicalId":19487,"journal":{"name":"Oncology Reviews","volume":"15 1","pages":"519"},"PeriodicalIF":3.6,"publicationDate":"2021-07-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/06/10/onco-15-1-519.PMC8273628.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39254643","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 6